Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy

References

• MathijssenRvan AlphenRJVerweijJClinical pharmacokinetics and metabolism of irinotecan (CPT-11)Clin Cancer Res2001782182219411489791
   PubMed Web of Science ®Google Scholar
• XiaoXGXiaSZouMThe relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancerOnco Targets Ther201583575358326664141
   PubMed Web of Science ®Google Scholar
• XuCTangXQuYKeyoumuSZhouNTangYUGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancerCancer Chemother Pharmacol201678111913027220761
   PubMed Web of Science ®Google Scholar
• KimMKeamBKimTMPhase II study of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancerCancer Res Treat201649241642227488873
   PubMedGoogle Scholar
• LopesFSmithRNashSMitchellRTSpearsNIrinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of pre-pubertal miceMol Hum Reprod20162211745755 Epub 2016 Jul 2827470502
   PubMedGoogle Scholar
• FujitaKSparreboomAPharmacogenetics of irinotecan disposition and toxicity: a reviewCurr Clin Pharmacol20105320921720406168
   PubMedGoogle Scholar
• KawatoYAonumaMHirotaYKugaHSatoKIntracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11Cancer Res19915116418741911651156
   PubMed Web of Science ®Google Scholar
• MiyataYTouyamaTKusumiTUDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancerInt J Clin Oncol201621469670326710796
   PubMed Web of Science ®Google Scholar
• YehYSTsaiHLHuangCWProspective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trialTrials2016174626811156
   PubMedGoogle Scholar
• ShimoyamaSPharmacogenetics of irinotecan: an ethnicity-based prediction of irinotecan adverse eventsWorld J Gastrointest Surg201021142121160829
   PubMedGoogle Scholar
• InoueKSonobeMKawamuraYPolymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapyTohoku J Exp Med2013229210711423303296
   PubMed Web of Science ®Google Scholar
• LiuXHLuJDuanWPredictive value of UGT1A1*28 polymorphism in irinotecan-based chemotherapyJ Cancer20178469170328367249
   PubMed Web of Science ®Google Scholar
• LiMWangZGuoJClinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancerOnco Targets Ther201423716531661
   Google Scholar
• GaoJZhouJLiYLuMJiaRShenLUGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patientsMed Oncol201330360423686699
   PubMed Web of Science ®Google Scholar
• TakanoMYamamotoKTabataTImpact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinumAsia Pac J Clin Oncol201612211512426862009
   PubMedGoogle Scholar
• AtasilpCChansriwongPSirachainanECorrelation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patientsDrug Metab Pharmacokinet2016311909426830078
   PubMedGoogle Scholar
• DeekenJFFiggWDBatesSESparreboomAToward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogeneticsAnticancer Drugs200718211112617159598
   PubMed Web of Science ®Google Scholar
• LeeWLockhartACKimRBRothenbergMLCancer pharmacogenomics: powerful tools in cancer chemotherapy and drug developmentOncologist200510210411115709212
   PubMed Web of Science ®Google Scholar
• DeekenJFSlackRMarshallJLIrinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the questionCancer200811371502151018720361
   PubMedGoogle Scholar
• StrassburgCPKalthoffSEhmerUVariability and function of family 1 uridine-5′-diphosphate glucuronosyltransferases (UGT1A)Crit Rev Clin Lab Sci200845648553019003600
   PubMed Web of Science ®Google Scholar
• ShulmanKCohenIBarnett-GrinessOClinical implications of UGT1A1*28 genotype testing in colorectal cancer patientsCancer2011117143156316221287524
   PubMed Web of Science ®Google Scholar
• GagneJFMontminyVBelangerPJournaultKGaucherGGuillemetteCCommon human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)Mol Pharmacol200262360861712181437
   PubMed Web of Science ®Google Scholar
• WangYShenLXuNUGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracilWorld J Gastroenterol201218456635664423236239
   PubMed Web of Science ®Google Scholar
• KimTWInnocentiFInsights, challenges, and future directions in irinogeneticsTher Drug Monit200729326527017529881
   PubMed Web of Science ®Google Scholar
• HoskinsJMGoldbergRMQuPIbrahimJGMcLeodHLUGT1A1*28 genotype and irinotecan-induced neutropenia: dose mattersJ Natl Cancer Inst200799171290129517728214
   PubMedGoogle Scholar
• HirasawaAZamaTAkahaneTPolymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patientsJ Hum Genet2013581279479824088669
   PubMedGoogle Scholar
• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• DouillardJYCunninghamDRothADIrinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialLancet200035592121041104710744089
   PubMed Web of Science ®Google Scholar
• SaltzLBCoxJVBlankeCIrinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupN Engl J Med20003431390591411006366
   PubMed Web of Science ®Google Scholar
• McLeodHLSargentDJMarshSPharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741J Clin Oncol201028203227323320530282
   PubMed Web of Science ®Google Scholar
• GlimeliusBGarmoHBerglundAPrediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancerPharmacogenomics J2011111617120177420
   PubMed Web of Science ®Google Scholar